ARROWHEAD PHARMACEUTICALS, INC. - 8-K Filing
Arrowhead Pharmaceuticals reported fiscal 2026 second-quarter results for the period ended March 31, 2026, with revenue of $73.7 million compared to $542.7 million in the same period in 2025. The company reported a net loss of $132.7 million, or $0.93 per diluted share, compared to a net income of $370.4 million, or $2.75 per diluted share, in the prior year. The filing also highlighted key developments, including the continued commercial momentum of REDEMPLO, regulatory approvals in multiple geographies, and a $25 million upfront payment from Madrigal Pharmaceuticals for the licensing of ARO-... (Items: 2.02 Results of Operations and Financial Condition On May 7, 2026, Arrowhead Pharmaceuticals, Inc, 9.01 Financial Statements and Exhibits)
Tickers: $ARWR